|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lam KC and Mok TS: Targeted therapy: An
evolving world of lung cancer. Respirology. 16:13–21. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mack PC, Redman MW, Chansky K, Williamson
SK, Farneth NC, Lara PN Jr, Franklin WA, Le QT, Crowley JJ and
Gandara DR; SWOG, : Lower osteopontin plasma levels are associated
with superior outcomes in advanced non-small-cell lung cancer
patients receiving platinum-based chemotherapy: SWOG study S0003. J
Clin Oncol. 26:4771–4776. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rizvi NA, Hellmann MD, Brahmer JR,
Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie
SA, Goldman JW, et al: Nivolumab in combination with platinum-based
doublet chemotherapy for first-line treatment of advanced
non-small-cell lung cancer. J Clin Oncol. 34:2969–2979. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang Q, Chen Y, Feng H, Zhang B and Wang
H: Prognostic and predictive value of HURP in nonsmall cell lung
cancer. Oncol Rep. 39:1682–1692. 2018.PubMed/NCBI
|
|
6
|
Mashouri L, Yousefi H, Aref AR, Ahadi AM,
Molaei F and Alahari SK: Exosomes: Composition, biogenesis, and
mechanisms in cancer metastasis and drug resistance. Mol Cancer.
18:752019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
H Rashed M, Bayraktar E, K Helal G,
Abd-Ellah MF, Amero P, Chavez-Reyes A and Rodriguez-Aguayo C:
Exosomes: From garbage bins to promising therapeutic targets. Int J
Mol Sci. 18:5382017. View Article : Google Scholar
|
|
8
|
Ludwig AK and Giebel B: Exosomes: Small
vesicles participating in intercellular communication. Int J
Biochem Cell Biol. 44:11–15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim DH, Park S, Kim H, Choi YJ, Kim SY,
Sung KJ, Sung YH, Choi CM, Yun M, Yi YS, et al: Tumor-derived
exosomal miR-619-5p promotes tumor angiogenesis and metastasis
through the inhibition of RCAN1.4. Cancer Lett. 475:2–13. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sandfeld-Paulsen B, Jakobsen KR, Bæk R,
Folkersen BH, Rasmussen TR, Meldgaard P, Varming K, Jørgensen MM
and Sorensen BS: Exosomal proteins as diagnostic biomarkers in lung
cancer. J Thorac Oncol. 11:1701–1710. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Del Vescovo V and Denti MA: microRNA and
lung cancer. Adv Exp Med Biol. 889:153–177. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Czarnecka KH, Szmyd B, Baranska M,
Kaszkowiak M, Kordiak J, Antczak A, Pastuszak-Lewandoska D and
Brzeziańska-Lasota E: A strong decrease in TIMP3 expression
mediated by the presence of miR-17 and 20a enables extracellular
matrix remodeling in the NSCLC lesion surroundings. Front Oncol.
9:13722019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hu G, Drescher KM and Chen XM: Exosomal
miRNAs: Biological properties and therapeutic potential. Front
Genet. 3:562012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yoshii S, Hayashi Y, Iijima H, Inoue T,
Kimura K, Sakatani A, Nagai K, Fujinaga T, Hiyama S, Kodama T, et
al: Exosomal microRNAs derived from colon cancer cells promote
tumor progression by suppressing fibroblast TP53 expression. Cancer
Sci. 110:2396–2407. 2019.PubMed/NCBI
|
|
15
|
Berrout J, Kyriakopoulou E, Moparthi L,
Hogea AS, Berrout L, Ivan C, Lorger M, Boyle J, Peers C, Muench S,
et al: TRPA1-FGFR2 binding event is a regulatory oncogenic driver
modulated by miRNA-142-3p. Nat Commun. 8:9472017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu K, Liu S, Zhang W, Jia B, Tan L, Jin Z
and Liu Y: miR-494 promotes cell proliferation, migration and
invasion, and increased sorafenib resistance in hepatocellular
carcinoma by targeting PTEN. Oncol Rep. 34:1003–1010. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao L, Liu W, Xiao J and Cao B: The role
of exosomes and ‘exosomal shuttle microRNA’ in tumorigenesis and
drug resistance. Cancer Lett. 356:339–346. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qin X, Yu S, Zhou L, Shi M, Hu Y, Xu X,
Shen B, Liu S, Yan D and Feng J: Cisplatin-resistant lung cancer
cell-derived exosomes increase cisplatin resistance of recipient
cells in exosomal miR-100-5p-dependent manner. Int J Nanomedicine.
12:3721–3733. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Drayton RM: The role of microRNA in the
response to cisplatin treatment. Biochem Soc Trans. 40:821–825.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huang L, Pan D, Chen Q, Zhu LJ, Ou J,
Wabitsch M and Wang YX: Transcription factor Hlx controls a
systematic switch from white to brown fat through Prdm16-mediated
co-activation. Nat Commun. 8:682017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tusher VG, Tibshirani R and Chu G:
Significance analysis of microarrays applied to the ionizing
radiation response. Proc Natl Acad Sci USA. 98:5116–5121. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang YH, Liang KH, Chien RN, Hu TH, Lin
KH, Hsu CW, Lin CL, Pan TL, Ke PY and Yeh CT: A Circulating
MicroRNA signature capable of assessing the risk of hepatocellular
carcinoma in cirrhotic patients. Sci Rep. 7:5232017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang HG and Grizzle WE: Exosomes and
cancer: A newly described pathway of immune suppression. Clin
Cancer Res. 17:959–964. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fan Z, Yu J, Lin J, Liu Y and Liao Y:
Exosome-specific tumor diagnosis via biomedical analysis of
exosome-containing microRNA biomarkers. Analyst. 144:5856–5865.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zarogoulidis K, Zarogoulidis P, Darwiche
K, Boutsikou E, Machairiotis N, Tsakiridis K, Katsikogiannis N,
Kougioumtzi I, Karapantzos I, Huang H and Spyratos D: Treatment of
non-small cell lung cancer (NSCLC). J Thorac Dis. 5 (Suppl
4):S389–S396. 2013.PubMed/NCBI
|
|
28
|
Barr MP, Gray SG, Hoffmann AC, Hilger RA,
Thomale J, O'Flaherty JD, Fennell DA, Richard D, O'Leary JJ and
O'Byrne KJ: Generation and characterisation of cisplatin-resistant
non-small cell lung cancer cell lines displaying a stem-like
signature. PLoS One. 8:e541932013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ma Y, Yuwen D, Chen J, Zheng B, Gao J, Fan
M, Xue W, Wang Y, Li W, Shu Y, et al: Exosomal transfer of
cisplatin-induced miR-425-3p confers cisplatin resistance In NSCLC
through activating autophagy. Int J Nanomedicine. 14:8121–8132.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lara PN Jr, Gandara DR, Longmate J,
Gumerlock PH, Lau DH, Edelman MJ, Gandour-Edwards R, Mack PC,
Israel V, Raschko J, et al: Activity of high-dose toremifene plus
cisplatin in platinum-treated non-small-cell lung cancer: A phase
II California cancer consortium trial. Cancer Chemother Pharmacol.
48:22–28. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xiao X, Yu S, Li S, Wu J, Ma R, Cao H, Zhu
Y and Feng J: Exosomes: Decreased sensitivity of lung cancer A549
cells to cisplatin. PLoS One. 9:e895342014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang Z, Li X, Sun W, Yue S, Yang J, Li J,
Ma B, Wang J, Yang X, Pu M, et al: Loss of exosomal miR-320a from
cancer-associated fibroblasts contributes to HCC proliferation and
metastasis. Cancer Lett. 397:33–42. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang Q, Zhang C, Ma JX, Ren H, Sun Y and
Xu JZ: Circular RNA PIP5K1A promotes colon cancer development
through inhibiting miR-1273a. World J Gastroenterol. 25:5300–5309.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kooijmans SA, Schiffelers RM, Zarovni N
and Vago R: Modulation of tissue tropism and biological activity of
exosomes and other extracellular vesicles: New nanotools for cancer
treatment. Pharmacol Res. 111:487–500. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jana S, Sengupta S, Biswas S, Chatterjee
A, Roy H and Bhattacharyya A: miR-216b suppresses breast cancer
growth and metastasis by targeting SDCBP. Biochem Biophys Res
Commun. 482:126–133. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Talukdar S, Das SK, Pradhan AK, Emdad L,
Windle JJ, Sarkar D and Fisher PB: MDA-9/syntenin (SDCBP) is a
critical regulator of chemoresistance, survival and stemness in
prostate cancer stem cells. Cancers (Basel). 12:532019. View Article : Google Scholar
|
|
37
|
Cui M, Wang H, Yao X, Zhang D, Xie Y, Cui
R and Zhang X: Circulating MicroRNAs in cancer: Potential and
challenge. Front Genet. 10:6262019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jiang C, Hopfner F, Katsikoudi A, Hein R,
Catli C, Evetts S, Huang Y, Wang H, Ryder JW, Kuhlenbaeumer G, et
al: Serum neuronal exosomes predict and differentiate Parkinson's
disease from atypical parkinsonism. J Neurol Neurosurg Psychiatry.
91:720–729. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhao X, Dou J, Cao J, Wang Y, Gao Q, Zeng
Q, Liu W, Liu B, Cui Z, Teng L, et al: Uncovering the potential
differentially expressed miRNAs as diagnostic biomarkers for
hepatocellular carcinoma based on machine learning in the cancer
genome atlas database. Oncol Rep. 43:1771–1784. 2020.PubMed/NCBI
|
|
40
|
Pullan JE, Confeld MI, Osborn JK, Kim J,
Sarkar K and Mallik S: Exosomes as drug carriers for cancer
therapy. Mol Pharm. 16:1789–1798. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fan Z, Xiao K, Lin J, Liao Y and Huang X:
Functionalized DNA enables programming exosomes/vesicles for tumor
imaging and therapy. Small. 15:e19037612019. View Article : Google Scholar : PubMed/NCBI
|
